Published By

Around the Blogosphere: Pharmaceutical Representatives Reap Millions as Whistleblowers

Anytime we at the CAFA Law Blog see a post that has “millions” in the headline, we’re interested. Even though this post doesn’t directly relate to our bread and butter, the Class Action Fairness Act, we thought our readers might be interested in this post from the Class Action Blog describing some recent qui tam actions, with settlements in the 10-figure (yes, billions, with a “B”) range in the pharmaceutical industry in which the relator ended up with 7 and 8 figure fees. Interesting stuff – take a look.

Pharmaceutical Representatives Reap Millions As Whistleblowers

Posted by Jerome Noll

More so than ever, pharmaceutical companies are getting caught offering incentives to their sales representatives to advocate to medical providers to prescribe their medications for off-label use. That is, for use in treating various diseases which have not been approved by the Food & Drug Administration (“FDA”). As a result, a number of pharmaceutical representatives have reaped huge rewards from successful Qui-Tam actions which are lawsuits filed under the False Claims Act. [Read the rest of the post here.]

Posted By McGlinchey Stafford at 07:46 AM | Comments / Questions (0)